Connect with us

News

Cannabis data platform strikes deal with Europe’s largest CBD producer

Published

on

The deal will help developers expand Efixii for commercial use

Medical cannabis data platform Global Cannabis Applications Corporation (GCAC) has signed a $0.4 million deal with Europe’s largest producer of CBD oil.

Chain-of-custody compliance and data platform, GCAC will supply QR Codes on the retail packaging of CBD Agrocasa.

GCAC’s Efixii platform attests to a CBD products’ life cycle, from seed to sale.

It is the only cannabis data platform in the world that acquires actual user-efficacy data on CBD consumption using its Efixii app – now available on Apple and Google’s Play Store.

The agreement is for the firms Efixii QR Codes to be applied to an initial retail rollout of 400 liters of CBD oil tinctures, containing approximately two million grams of cannabis.

Agrocasa focuses on producing the highest quality, authentic European CBD products using its Pharma-Grade EU GMP certified standard.

The company has the largest managed-grow operations of hemp inside Europe with a harvest capacity in excess of 4,000 ha. that produced approximately 24,000 liters of concentrated CBD oils in 2020.

“We are really looking forward to showcasing the power of Efixii’s truthful cannabis pre-consumption grow-data, coupled with Efixii’s post-consumption efficacy feedback-collection with Agrocasa’s retail products, said Brad Moore, CEO of GCAC.

“This $400k deal is for an initial run to enhance consumer confidence in Agrocasas’ products and add an amazing feedback-loop for Agrocasa to fine-tune their grows of local strains sourced from the EU Plant Variety database.”

Gabriel Luca, CEO of Agrocasa added: “The way in which Efixii uses blockchain to ensure the truth behind cultivators’ claims of CBD content, and the simplicity of its app-approach in capturing consumer feedback, is what drew us to license Efixii.

“We are HACCP compliant, Novelty Food registered and EU GMP certified and now, by adding consumer efficacy to the mix, Efixii could allow us to better plan our strain cultivations based on a strains efficacy in a given market vertical.”

Subject to a successful collection of efficacy data in the initial 400 liter run, both parties will work to expand the commercial use of Efixii across Agrocasa’s harvests in the future.

Sarah Sinclair is an award-winning freelance journalist covering health, drug policy and social affairs. She is one of the few UK reporters specialising in medical cannabis policy and as the former editor of Cannabis Health has covered developments in the European cannabis sector extensively, with a focus on patients and consumers. She continues to report on cannabis-related health and policy for Forbes, Cannabis Health and Business of Cannabis and has written for The i Paper, Byline Times, The Lead, Positive News, Leafie & others. Sarah has an NCTJ accreditation and an MA in Journalism from the University of Sunderland and has completed additional specialist training through the Medical Cannabis Clinicians Society in the UK. She has spoken at leading industry events such as Cannabis Europa.

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2024 PP Intelligence Ltd.